TheraDoc competitors and alternatives for antibiogram reporting and antimicrobial stewardship

TheraDoc competitors compared

The table below describes each product only from its own public product pages, read in September 2026. A blank means the vendor does not say it publicly, not that the product lacks it. Antimicrobe is not affiliated with Premier, Wolters Kluwer, Inovalon, BD or Epic.

Sentri7 is the closest like-for-like replacement

If you want to replace TheraDoc with another full surveillance platform, Sentri7 is the one to put on the shortlist first. Wolters Kluwer's stewardship page describes prioritized alerts from rules applied to real-time patient data, one-click AUR submission to NHSN under ONC certification, SAAR benchmarking, and an interactive dashboard that it says can produce an antibiogram in seconds. Many pharmacies already hold a Wolters Kluwer contract for UpToDate or Medi-Span, which often matters more in a procurement committee than any feature.

It also holds the current customer-satisfaction argument. In the 2026 Best in KLAS Software and Services report, released February 4, 2026, Sentri7 was ranked first for both Pharmacy Surveillance and Infection Control and Monitoring, according to Wolters Kluwer's announcement. Premier's TheraDoc page does not mention KLAS. If your committee asks why you are still on TheraDoc, expect that ranking to come up, and ask KLAS for the underlying interviews rather than relying on the headline.

VigiLanz is the second name most teams hear, and the thing to know in 2026 is that it is no longer an independent company. Inovalon bought it in 2024, and vigilanz.com now presents Inovalon's care management suite, with pharmacy surveillance listed next to infection prevention, MDS intelligence and quality management. That is a fair question to raise at renewal: who owns the roadmap, and who supports the interface in three years.

BD HealthSight Clinical Advisor comes from the pharmacy automation side. BD describes it as identifying potentially inappropriate antibiotic prescribing and sending near real-time alerts, with the companion Infection Advisor (formerly MedMined) covering healthcare-associated infection surveillance. It is most natural in a hospital that already runs BD dispensing and pharmacy analytics.

We compared the three largest platforms in much more depth, including what each needs from your IT team, in Sentri7 vs TheraDoc vs VigiLanz, and the tier-by-tier view of Inovalon's product is on the VigiLanz alternatives and competitors page.

If BD is the platform you are leaving instead, see MedMined and BD HealthSight alternatives.

The Epic stewardship module, if you are already on Epic

For an Epic hospital, the honest first alternative to any third-party platform is the stewardship module you may already be licensed for. Published hospital experience describes what it takes. Johns Hopkins, writing in the American Journal of Health-System Pharmacy in 2021, built customized stewardship alerts and scoring to triage patients, and reported that it needed stewardship physicians and pharmacists working with Epic IT staff, concluding that customizing the module requires significant time and expertise. The University of Vermont Medical Center described four years of optimizing its Epic foundation after its 2019 transition.

So the Epic route trades a vendor contract for internal build time. That is often the right trade for a large academic center with an Epic analyst assigned to pharmacy, and often the wrong one for a community hospital whose build request sits in a queue behind every other clinical priority.

What Antimicrobe replaces, and what it does not

Antimicrobe is not a like-for-like TheraDoc replacement, and it would be misleading to sell it as one. It does not fire real-time alerts, it does not submit AUR data to NHSN, it does not compute healthcare-associated infection definitions, and it does not connect to your EHR. If your stewardship pharmacists work a TheraDoc worklist every morning, keep the worklist.

What it does replace is the part most platforms treat as an afterthought: the cumulative antibiogram. You export a year or more of finalized susceptibility results from the LIS as a CSV, and the builder de-duplicates to the first isolate per patient, suppresses cells under 30 isolates the way CLSI M39 recommends, cuts by unit, source and quarter, and ranks empiric options by local percent susceptible. Every rule is printed on the report, so a committee can see what each number rests on.

That gives two realistic patterns. A hospital that keeps TheraDoc for alerting can stop rebuilding the antibiogram by hand and run it here from the same lab data. A smaller hospital that never needed real-time surveillance can skip the platform entirely and cover the resistance half of stewardship tracking with a CSV and a browser.

• Replaces: the annual antibiogram spreadsheet, the unit and source cuts, the quarterly trend, the committee pack
• Does not replace: real-time alerts, NHSN AUR submission, HAI surveillance, EHR integration
• Runs alongside: TheraDoc, Sentri7, VigiLanz, BD HealthSight or Epic, from the same lab export

Questions to ask any TheraDoc competitor on the demo

Vendor demos are built to show alerts firing. The questions below are about the parts that decide whether the product works for your committee and your budget, and every vendor should answer them in writing.

• Does the antibiogram de-duplicate to the first isolate per patient per period, and can we see that rule on the printed report?
• Which suppression threshold is applied, and are cells under 30 isolates shown as counts rather than percentages?
• Which CLSI M100 breakpoint version is used, and how is a breakpoint change flagged in the trend?
• Can a pharmacist cut the report by unit, source and quarter without opening a vendor ticket?
• What is the price per bed or per facility, in writing, before the demo?
• How long is the interface build, who pays for it, and what happens to our historical data if we leave?

Switching without a gap in reporting

You do not need to switch anything on a single day. The sensible path is to run the new report in parallel for one reporting period and compare it to the last antibiogram your current system produced. When the numbers differ, the cause is almost always one of two settings: how repeat isolates were de-duplicated, and whether intermediate results were counted as susceptible or not. Both are visible switches in the builder, so you can reproduce the old logic before you decide whether to keep it.

The export itself is usually the easy part. Our guide to pulling the susceptibility export from your LIS lists the seven fields needed, and the hospital antibiogram page shows what the finished cumulative report looks like.

Who should stay on TheraDoc

Stay if your team works real-time alerts every day and the interface is stable, if you rely on it for NHSN reporting, if you are a VA facility inside the DSS relationship, or if your network includes post-acute beds that Premier covers and competitors do not mention. Replacing a platform that is doing its job to save money on one report is a poor trade. In that case the better move is to keep TheraDoc and take the antibiogram off its plate.